Decoding the tumor-aging axis: from bench to clinical.
Aging and cancer share common cellular drivers—senescence, inflammation, immune decline—opening new treatment angles at their intersection.
This Frontiers in Immunology review synthesizes current understanding of the bidirectional relationship between aging biology and cancer, covering shared molecular drivers including senescence, chronic inflammation, immune dysfunction, and metabolic reprogramming. The authors trace translational pathways from bench findings to emerging clinical strategies targeting the tumor-aging interface, including senolytics and age-adapted immunotherapy.
What the study was
- Study design
- Narrative review
- Population
- Adults with age-related cancers; aging-cancer interface at cellular and clinical levels
- Category
- Other
- Maturity
- Exploratory
- Journal
- Frontiers in Immunology
Why it surfaced
Comprehensive tumor-aging intersection review with pmcrefcount=215 indicating high citation activity; PMC open-access; relevant to aging watchlist and cancer biology intersection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.